See our coverage on
What’s New in 2024
We are raring to go this January, humbled to be with all of you for another year, missing those who are no longer with us, and implementing a strong plan to build on I AM ALS’ impact over the last few years.
I AM ALS Update on Five Years of Operations and a Future Ahead
A Note from the I AM ALS Board Treasurer
We will find cures for ALS. The only question is when. That answer depends on you.
Stay informed on I AM ALS’ progress and what you can do to help us make hope real.
NurOwn AdComm: What happened? What’s next?
There have been a lot of conversations about NurOwn’s Cellular, Tissue, and Gene Therapies Advisory Committee (AdComm) meeting that occurred on September 27, 2023, the subsequent Biologics License Applications (BLA) removal, and its perceived irregularities.
UPDATE: Promising Pathway Act: Senate Hearing Sheds Light on the Challenges of Getting Access to Treatments for Diseases like ALS – October 26, 2023
On October 26, 2023, the United States Senate Special Committee on Aging held a hearing: Unlocking Hope: Access to Therapies for People with Rare, Progressive, and Serious Diseases. Here’s what unfolded and what it means for people living with ALS, their caregivers and loved ones, and access to future medical advancements.
I AM ALS statement on BrainStorm’s withdrawal of BLA for NurOwn
We are disappointed to learn that BrainStorm withdrew its FDA Biologics License Application for NurOwn.
I AM ALS proud to be among 2023 PRWeek Purpose Award Finalists
I AM ALS congratulates Adidas & Current Global for being named winner of the 2023 PRWeek Purpose Award for Best Advocacy campaign.
NINDS awards three Expanded Access Program grants under the Accelerating Access to Critical Therapies for ALS (ACT for ALS)
I AM ALS is pleased to see that the National Institute of Neurological Disorders and Stroke (NINDS) announced three Expanded Access Program (EAP) grants to help people with Amyotrophic Lateral Sclerosis (ALS) who do not qualify for clinical trials.